Cargando…

Adjunctive Melatonin for Tardive Dyskinesia in Patients with Schizophrenia: A Meta-Analysis

BACKGROUND: Tardive dyskinesia (TD) is characterized by abnormal and involuntary movements. Importantly, TD could cause considerable personal suffering and social and physical disabilities. AIMS: This meta-analysis based on randomized controlled trials (RCTs) systematically assessed the therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: NG, Chee H., UNGVARI, Gabor S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shanghai Municipal Bureau of Publishing 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579456/
https://www.ncbi.nlm.nih.gov/pubmed/28904507
http://dx.doi.org/10.11919/j.issn.1002-0829.217046
_version_ 1783260706598027264
author NG, Chee H.
UNGVARI, Gabor S.
author_facet NG, Chee H.
UNGVARI, Gabor S.
collection PubMed
description BACKGROUND: Tardive dyskinesia (TD) is characterized by abnormal and involuntary movements. Importantly, TD could cause considerable personal suffering and social and physical disabilities. AIMS: This meta-analysis based on randomized controlled trials (RCTs) systematically assessed the therapeutic effect and tolerability of melatonin for TD in schizophrenia. METHODS: A computerized and systematical search of both Chinese (Wanfang Data, Chinese National Knowledge Infrastructure (CNKI), SINOMED) and English (PubMed, PsycINFO, Embase, Cochrane Library databases) databases, from their inception until June 8, 2017, was conducted by two independent authors. The severity of TD symptoms were the primary outcome measure and analyzed using a random effects model by the Review Manager (RevMan) Version 5.3. Quality evaluation of included RCTs was conducted using the Cochrane risk of bias and Jadad scale. The GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) system recommendation grading method was used to assess the overall quality level of meta-analytic outcomes. RESULTS: Four RCTs (n=130) were identified and analyzed. Three RCTs used double blind and 1 RCT used masked assessors using the Cochrane risk of bias, and 3 RCTs were rated as high quality based on Jadad scale. Compared with the control group, adjunctive melatonin was superior in reducing the severity of TD as measured by the Abnormal Involuntary Movement Scale (AIMS) (4 RCTs, n=130, weighted mean difference (WMD): -1.52 (95% confidence intervals (CI): -3.24, 0.20), p=0.08; I(2)=0%) although the improvement did not reach a significant level. The overall evidence quality of the improvement of TD symptoms, according to GRADE approach, was rated as “Low”. The data on the ADRs and cognitive effect were limited. CONCLUSIONS: This meta-analysis shows that melatonin has potential for improving TD symptoms in schizophrenia. Future higher quality and larger RCTs are warranted to confirm the findings.
format Online
Article
Text
id pubmed-5579456
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Shanghai Municipal Bureau of Publishing
record_format MEDLINE/PubMed
spelling pubmed-55794562017-09-13 Adjunctive Melatonin for Tardive Dyskinesia in Patients with Schizophrenia: A Meta-Analysis NG, Chee H. UNGVARI, Gabor S. Shanghai Arch Psychiatry Systematic Review and Meta-Analysis BACKGROUND: Tardive dyskinesia (TD) is characterized by abnormal and involuntary movements. Importantly, TD could cause considerable personal suffering and social and physical disabilities. AIMS: This meta-analysis based on randomized controlled trials (RCTs) systematically assessed the therapeutic effect and tolerability of melatonin for TD in schizophrenia. METHODS: A computerized and systematical search of both Chinese (Wanfang Data, Chinese National Knowledge Infrastructure (CNKI), SINOMED) and English (PubMed, PsycINFO, Embase, Cochrane Library databases) databases, from their inception until June 8, 2017, was conducted by two independent authors. The severity of TD symptoms were the primary outcome measure and analyzed using a random effects model by the Review Manager (RevMan) Version 5.3. Quality evaluation of included RCTs was conducted using the Cochrane risk of bias and Jadad scale. The GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) system recommendation grading method was used to assess the overall quality level of meta-analytic outcomes. RESULTS: Four RCTs (n=130) were identified and analyzed. Three RCTs used double blind and 1 RCT used masked assessors using the Cochrane risk of bias, and 3 RCTs were rated as high quality based on Jadad scale. Compared with the control group, adjunctive melatonin was superior in reducing the severity of TD as measured by the Abnormal Involuntary Movement Scale (AIMS) (4 RCTs, n=130, weighted mean difference (WMD): -1.52 (95% confidence intervals (CI): -3.24, 0.20), p=0.08; I(2)=0%) although the improvement did not reach a significant level. The overall evidence quality of the improvement of TD symptoms, according to GRADE approach, was rated as “Low”. The data on the ADRs and cognitive effect were limited. CONCLUSIONS: This meta-analysis shows that melatonin has potential for improving TD symptoms in schizophrenia. Future higher quality and larger RCTs are warranted to confirm the findings. Shanghai Municipal Bureau of Publishing 2017-06-25 2017-06-25 /pmc/articles/PMC5579456/ /pubmed/28904507 http://dx.doi.org/10.11919/j.issn.1002-0829.217046 Text en © Shanghai Municipal Bureau of Publishing http://creativecommons.org/licenses/by-nc/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
spellingShingle Systematic Review and Meta-Analysis
NG, Chee H.
UNGVARI, Gabor S.
Adjunctive Melatonin for Tardive Dyskinesia in Patients with Schizophrenia: A Meta-Analysis
title Adjunctive Melatonin for Tardive Dyskinesia in Patients with Schizophrenia: A Meta-Analysis
title_full Adjunctive Melatonin for Tardive Dyskinesia in Patients with Schizophrenia: A Meta-Analysis
title_fullStr Adjunctive Melatonin for Tardive Dyskinesia in Patients with Schizophrenia: A Meta-Analysis
title_full_unstemmed Adjunctive Melatonin for Tardive Dyskinesia in Patients with Schizophrenia: A Meta-Analysis
title_short Adjunctive Melatonin for Tardive Dyskinesia in Patients with Schizophrenia: A Meta-Analysis
title_sort adjunctive melatonin for tardive dyskinesia in patients with schizophrenia: a meta-analysis
topic Systematic Review and Meta-Analysis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579456/
https://www.ncbi.nlm.nih.gov/pubmed/28904507
http://dx.doi.org/10.11919/j.issn.1002-0829.217046
work_keys_str_mv AT adjunctivemelatoninfortardivedyskinesiainpatientswithschizophreniaametaanalysis
AT adjunctivemelatoninfortardivedyskinesiainpatientswithschizophreniaametaanalysis
AT adjunctivemelatoninfortardivedyskinesiainpatientswithschizophreniaametaanalysis
AT adjunctivemelatoninfortardivedyskinesiainpatientswithschizophreniaametaanalysis
AT ngcheeh adjunctivemelatoninfortardivedyskinesiainpatientswithschizophreniaametaanalysis
AT ungvarigabors adjunctivemelatoninfortardivedyskinesiainpatientswithschizophreniaametaanalysis
AT adjunctivemelatoninfortardivedyskinesiainpatientswithschizophreniaametaanalysis
AT adjunctivemelatoninfortardivedyskinesiainpatientswithschizophreniaametaanalysis
AT adjunctivemelatoninfortardivedyskinesiainpatientswithschizophreniaametaanalysis
AT adjunctivemelatoninfortardivedyskinesiainpatientswithschizophreniaametaanalysis